The case was discussed in a multidisciplinary group, and it was decided to start systemic treatment with an aromatase inhibitor and a CDK 4/6 inhibitor, as indicated in advanced hormone receptor-positive and HER2-negative breast carcinomas, as first-line systemic treatment. Here, ERBB2 is linked to breast carcinoma.